Sorrento Therapeutics (NASDAQ: SRNE), a clinical-stage biotech, is off to a strong start this week. The drugmaker's shares are up by a healthy 42.6% in pre-market trading Monday morning.
Last Friday, Sorrento's shares gained an astounding 158% in response to the company's announcement that it may have hit upon a highly effective preventative treatment for the novel coronavirus. This potential game-changer is an experimental antibody known as STI-1499. Today's double-digit move higher appears to be a continuation of last week's sizable rally.
Image source: Getty Images.